KESHO

Advancing Breast Cancer Survivorship Care in Kenya
2025-10-23 19:00 - 20:30 (Africa/Nairobi)
Theme: Evidence, Outcomes & Psychosocial PerspectivesDate: 23rd October 2025Time: 7:00 PM – 8:30 PM EATCPD Accredited
Speakers & Topics:
1. Zahra Haji

Psycho-oncologist & Associate Scientist
Psychosocial Oncology Lead, DART Lead Kenya; Aga Khan University Hospital Nairobi
Topic: The Emotional Journey of Survivorship: Addressing Psychological Well-being after Breast Cancer

2. Prisca Githuka

Vice-Chairperson & Advocacy Chair, Kenyan Network of Cancer Organizations (KENCO); Chairlady, Cancer Survivors Association of Kenya; Founder and Team Leader – Pink Hearts Cancer Support Foundation
Topic: Lived Experience of Breast Cancer Survivors in Kenya: Gaps and Implications for Care

3. Dr. Joyfrida Chepchumba

Pharmacist & Program Officer – Treatment, Palliative Care and Survivorship Pillar, National Cancer Control Program
Topic: Policy Frameworks for Breast Cancer Survivorship Care in Kenya

4. Lyagamula (Gammy) Kisia

Research Officer, African Population and Health Research Center (APHRC), Kenya
Topic: Breast Cancer Survivorship in Kenya: Key Findings from a Pilot Study

Moderator: Dr. Miriam Mutebi

Consultant Breast Surgical Oncologist & Health Systems Researcher, Aga Khan University in Nairobi, Kenya

Organizers & Partners:

KESHO (Kenya Society of Hematology & Oncology)
NCCP (National Cancer Control Programme)
KILELE Health Association
KENCO (Kenyan Network of Cancer Organizations)
APHRC (African Population and Health Research Center)

Multidisciplinary Management of Hepatocellular Carcinoma
2025-10-30 19:00 - 20:30
Multidisciplinary Management of Hepatocellular Carcinoma(CPD Accredited)
Date: 30th October 2025Time: 7:00 PM – 8:30 PM EAT
Moderator:Dr. Wycliffe KaishaConsultant Gastrointestinal & Hepato-Bilio-Pancreatic Surgeon, Hercules Healthcare
Speakers:

Dr. Gladwell KiarieMedical Oncologist, The Nairobi HospitalTopic: The Medical Oncologists’ Role in HCC: Emerging Trends
Dr. Eric MurungaConsultant Physician, Gastroenterologist; Chairman, Gastroenterology Society of KenyaTopic: Management of Hepatitis B in Low-Resource Settings
Dr. Samuel NgukuConsultant, Radiology and Nuclear Medicine, Aga Khan University Hospital, NairobiTopic: Imaging of Hepatocellular Carcinoma

Organized by:Kenya Society of Haematology & Oncology (KESHO)
Partner:Beacon Medicare Limited(Global Marketing Partner of BEACON Pharmaceuticals Limited)
Summary:
The Chronic Liver Disease–Hepatocellular Carcinoma Continuum: Practical Clinical Updates
Presentations by Dr Gladwell Kiarie and Dr Eric Murunga
Two complementary presentations examined the clinical continuum linking chronic liver disease to hepatocellular carcinoma (HCC), with a focus on pragmatic, evidence-based approaches applicable to resource-limited settings.
Dr Gladwell Kiarie reviewed the medical management of hepatocellular carcinoma, emphasizing the importance of stage-guided, individualized care. Using established staging frameworks, she highlighted how tumor burden, liver function and patient performance status collectively inform treatment selection. The discussion underscored the evolving role of systemic therapies, including immunotherapy and targeted agents, alongside locoregional modalities such as trans arterial therapies and radiotherapy. The need for multidisciplinary decision-making, early referral and appropriate patient selection was reinforced as critical to improving outcomes in HCC.
Dr Eric Murunga addressed the management of chronic Hepatitis B within real-world, resource-constrained contexts. He outlined practical diagnostic pathways, treatment eligibility criteria and monitoring strategies aligned with contemporary guidelines. Emphasis was placed on simplified fibrosis assessment tools, long-term antiviral therapy and structured follow-up. Preventive strategies including screening, vaccination of contacts and hepatocellular carcinoma surveillance were highlighted as essential interventions to reduce progression to cirrhosis and liver cancer.
Together, the presentations reinforced the concept that HCC prevention and outcomes are intrinsically linked to effective upstream management of chronic liver disease, particularly viral hepatitis.
Key takeaway: Strengthening early identification and treatment of chronic Hepatitis B, alongside structured surveillance and stage-appropriate management of hepatocellular carcinoma, is central to reducing advanced liver cancer and improving survival in resource-limited settings.

Advances in Small-Cell Lung Cancer Treatment
2025-11-13 19:00 - 20:30
Date: 13th November 2025Time: 7 PM – 8:30 PM EAT

SpeakerDr. Riaz KasmaniMedical Oncologist, Mombasa Cancer CentreSmall-Cell Lung Cancer: Advances, Evidence and Clinical Challenges

ModeratorDr. Jumaa BwikaClinical Assistant Professor & Section Head, Pulmonology, Aga Khan Hospital

Organized by:KESHOKenya Society of Haematology & Oncology
Supported by:BEACON Medicare Limited(Global Marketing Partner of BEACON Pharmaceuticals Limited)
Summary:
Dr Kasmani presented an overview of Small Cell Lung Cancer (SCLC), focusing on disease biology, treatment response, relapse patterns and emerging research directions.
SCLC accounts for a minority of lung cancer diagnoses yet contributes disproportionately to cancer-related mortality due to its aggressive behavior, early dissemination and rapid development of treatment resistance. While the disease is initially highly chemo sensitive, with high response rates to first-line therapy, relapse is common and subsequent responses are often short-lived.
The presentation highlighted current staging approaches, standard first-line treatment strategies for limited and extensive-stage disease and the evolving role of chemo-immunotherapy. Emphasis was placed on response assessment, patterns of relapse and the clinical distinction between sensitive and refractory disease, which continues to guide second-line treatment decisions.
Key takeaway: Despite high initial response rates, SCLC remains a challenging disease with frequent relapses, underscoring the need for timely diagnosis, evidence-based treatment and continued investment in research and clinical trials to improve patient outcomes.

Management of Non-Small Cell Lung Cancer
2025-11-20 19:00 - 2025-11-22 20:30
BRIDGING DISCIPLINES:ADVANCES IN THE COMPREHENSIVEManagement of Non-Small Cell Lung Cancer
Date: 20th November 2025Time: 7 PM – 8:30 PM EAT
(CPD ACCREDITED)

Moderator
Dr. Muhindi WanjuguPhysician and Chest Specialist, The Nairobi Hospital, Doctors Plaza, Nairobi

Speakers
Dr. Nuruddin JoomaHaemato-Oncologist, Florida Cancer Specialists & Research Institute, USASystemic Therapy Advances in Non-Small-Cell Lung Cancer
Dr. Morris MuhingaConsultant Cardiothoracic Surgeon, The Nairobi HospitalShift in Surgical Paradigm
Summary:
Lung Cancer: Contemporary Clinical Management and Emerging Evidence
Presentations by Dr Nuruddin Jooma and Dr Morris Muhinga
The sessions delivered by Dr Nuruddin Jooma and Dr Morris Muhinga provided a clinically focused overview of lung cancer management, with emphasis on Non-Small Cell Lung Cancer (NSCLC) across early, locally advanced and metastatic diseases. The presentations underscored the central role of accurate histological classification, TNM staging and multidisciplinary evaluation in determining treatment intent and sequencing.
Key clinical principles discussed included optimal diagnostic pathways incorporating imaging, histopathology and immunohistochemistry, alongside the increasing importance of molecular profiling. Biomarker testing particularly for actionable driver mutations such as EGFR was highlighted as essential to guide therapy selection, avoid inappropriate use of immunotherapy and improve survival outcomes.
Current standards of care were reviewed across disease stages, including surgical management in early-stage disease, the expanding role of neoadjuvant and adjuvant systemic therapies, consolidation strategies following chemoradiation in locally advanced disease and the use of targeted therapies in molecularly defined metastatic NSCLC. Landmark clinical trials informing contemporary practice were referenced to illustrate evolving treatment paradigms.
Both presentations reinforced the need for timely diagnosis, biomarker-driven treatment decisions and coordinated multidisciplinary care, while acknowledging ongoing challenges related to access, treatment sequencing and long-term disease control.
Key takeaway: Optimal lung cancer outcomes depend on precise staging, comprehensive molecular testing and evidence-based, multidisciplinary treatment across the disease continuum.

Management of Pancreatic Cancer
2025-11-27 19:00 - 20:30
CPD ACCREDITED
Management of Pancreatic Cancer
Date:27th November 2025
Time:7 PM – 8:30 PM EAT

Moderator
Dr. Karan GandhiConsultant Hepatobiliary, General and Laparoscopic Surgeon at 3rd Park Hospital, Nairobi

SPEAKER
Dr. Sakulen A HarguraConsultant Hepatobiliary, General & Laparoscopic Surgeon, Kenyatta University Teaching, Research and Referral Hospital, NairobiTopic: Surgical Dilemmas in Pancreatic Cancer, “Who, When & How”

SPEAKER
Dr. Andrew OdhiamboMedical Oncologist – The Nairobi HospitalThematic Head & Program Director – Medical Oncology, UONTopic: Balancing Quality Vs Quantity of Life – Oncologist Role in Stage 4 Pancreatic Cancer
SPEAKER
Joyce AwuorConsultant Dietitian Nutritionist, Founder and CEO of DietSelect254Topic: The Ideal Diet for A Failing Pancreas
KESHOKenya Society of Haematology & Oncology

Cancer-Related Thrombosis
2025-12-04 19:00 - 20:30
Cancer-Associated Thrombosis: From Primary to Secondary Prophylaxis
Presentation by Dr Laura Kirui
Dr Laura Kirui delivered a focused clinical update on cancer-associated thrombosis (CAT), addressing its epidemiology, pathophysiology and evidence-based prevention and treatment strategies across the cancer care continuum.
The presentation highlighted the significantly increased risk of venous thromboembolism (VTE) among cancer patients and its associated morbidity and mortality. Mechanistic insights into cancer-driven hypercoagulability including inflammation, dysregulated fibrinolysis, and tumor host cellular interactions were reviewed to contextualize clinical risk.
Emphasis was placed on risk stratification, particularly the use of validated tools such as the Khorana score, to guide decisions on primary thromboprophylaxis. Data supporting the use of low molecular weight heparin and selected direct oral anticoagulants in high-risk populations were discussed, alongside bleeding considerations. The session also addressed therapeutic anticoagulation, duration of treatment, secondary prophylaxis and management in special scenarios including thrombocytopenia, catheter-related thrombosis and incidental VTE.
Key takeaway: Individualized risk assessment and ongoing reassessment are central to optimizing prevention and management of cancer-associated thrombosis.

Bladder and Urothelial Cancer Treatment
2025-12-11 19:00 - 20:30
Moderator:
Dr. Thomas OdenyMedical Oncologist, Assistant Professor of Medicine,Washington University in St. Louis
Speakers:
Dr. Primus OchiengLecturer, Programme Director – MMed Radiation Oncology& Founder, UNITED Oncology Clinical Trial Centre, UoNRadiotherapy in Bladder Cancer: Current Evidence and Clinical Applications
Dr. DK KimaniConsultant Surgeon & Urologist, Kenyatta National Hospital, NairobiBladder & Urothelial Cancer in Kenya: Bridging Treatment Innovations and Local Realities
Dr. Andrea ApolloSenior Investigator, Genitourinary Malignancies Branch, NCI, USAManagement of bladder cancer: Clinical trials and research updates

Multiple Myeloma
2025-12-22 08:00 - 17:00

Cervical Cancer Prevention and Control In Kenya
2026-01-22 19:00 - 20:30
(CPD Accredited)
Date & Time: 22nd January 2026 7 PM – 8:30 PM (EAT)

Moderator: Dr. Benjamin Elly Odongo
Obstetrician/Gynecologist & Gynaecologic Oncologist, Senior Lecturer & Chairman, Department of Obstetrics & Gynaecology, Kenyatta University School of Health Sciences

Speakers:
Prof. Lucy Muchiri
Associate Professor in the Department of Human Pathology, University of Nairobi’s School of Medicine
Topic: Overview of the WHO 90-70-90 cervical cancer elimination strategy and implications for pathology services
Prof. Omu Anzala Professor of Virology and Immunology, Department of Medical Microbiology; Senior Research Scientist at KAVI – Institute of Clinical Research (KAVI – ICR), University of Nairobi, Kenya
Topic: HPV Vaccination in Kenya: Scientific Evidence, Immunological Perspectives, and Public Controversies
Dr. Richa Bansal Gynecological Oncologist and Robotic Surgeon, Apollo Hospitals, Navi Mumbai, India
Topic: Cervical Cancer Prevention and Advanced Treatment
Highlights
This session examined cervical cancer through the lens of prevention, highlighting it as one of the few cancers where elimination is both feasible and within reach.
A central theme was the WHO 90-70-90 strategy, which outlines a clear pathway to elimination through HPV vaccination, screening and timely treatment. Achieving these targets could reduce cervical cancer incidence to below 4 cases per 100,000 women, effectively transforming it into a rare disease.
The discussion emphasized that cervical cancer is almost entirely driven by persistent HPV infection, making it uniquely preventable through vaccination and early detection. Evidence shows that HPV vaccines are highly effective, with strong and sustained protection against high-risk HPV types responsible for most cases.
Despite this, the burden remains disproportionately high in low- and middle-income settings, including Kenya, where gaps in screening coverage, diagnostic capacity and referral pathways continue to limit early detection and timely treatment.
The role of pathology services emerged as critical, forming the diagnostic backbone for screening programs and treatment decisions. Expanding HPV DNA testing, strengthening laboratory systems and investing in workforce development were identified as key priorities for achieving national targets.
Across the session, a consistent message emerged: cervical cancer is preventable and eliminating it will depend on scaling what already works.
Key Takeaways

Cervical cancer is one of the few cancers where elimination is achievable.
The WHO 90-70-90 targets provide a clear, evidence-based roadmap.
HPV vaccination and screening are high-impact prevention strategies.
Strengthening pathology and diagnostic capacity is essential to progress.
Closing gaps in access and coverage is critical to achieving equitable outcomes.

HPV Vaccine Campaign/Outreach Screening
2026-01-31 08:00 - 17:00

World Cancer Day
2026-02-05 19:00 - 20:30 | Virtual Event (Zoom), Kenya
World Cancer Day:
United by Unique – The Kenyan Perspective
Date: 5th February 2025Time: 7:00 PM – 8:30 PM (EAT)
Moderator
Dr. Gladwell KiarieMedical Oncologist, The Nairobi Hospital
Speakers
Hon. Dr. Ouma OlugaPrincipal Secretary for the State Department for Medical Services,Ministry of Health, Kenya
Hon. Dr. James NyikalChairperson of the National Assembly Departmental Committee on Health, Kenya
Dr. Mercy MwangangiChief Executive Officer, Social Health Authority
Dr. Elias MellyChief Executive Officer, National Cancer Institute, Kenya
Dr. Ahmed OgwellPublic Health Expert, CEO & President, VillageReach
Prisca GithukaVice-Chairperson & Advocacy Chair,Kenyan Network of Cancer Organizations (KENCO) and Chairlady,Cancer Survivors Association of Kenya
Highlights
This session brought together clinical, policy and advocacy voices to reflect on the current state of cancer care in Kenya, with a focus on how systems, leadership and lived experience intersect to shape outcomes.
A central theme was the need to move beyond fragmented approaches towards coordinated, patient-centered cancer control, grounded in national priorities and responsive to the realities of care delivery. The discussion highlighted that improving outcomes requires not only clinical excellence, but also alignment across policy, financing and implementation.
Speakers emphasized the importance of strengthening health systems to support prevention, early detection and access to treatment, while addressing structural barriers that continue to limit equitable care. The role of national institutions, policy frameworks and cross-sector collaboration emerged as critical in driving sustainable progress.
Patient voice and lived experience were also highlighted as essential to shaping responsive and inclusive cancer care strategies, ensuring that interventions reflect the needs and realities of those most affected.
Across the discussion, a consistent message emerged: meaningful progress in cancer control will depend on alignment between policy, practice and people.
Key Takeaways

Effective cancer control requires alignment across clinical care, policy and implementation.
Strengthening health systems is essential to improving access, equity and outcomes.
Prevention and early detection remain critical entry points for reducing burden.
Patient voice and lived experience are key to responsive, person-centered care.
Sustainable progress depends on multi-sector collaboration and leadership.

Watch the full session here:

Watch Video

Environmental Risks of Cancer
2026-02-12 08:00 - 17:00
Speakers: Dr. Mary Nyangasi, Dr. David Githanga, Dr. Carolina Espina
Date: 12 February 2026
Highlights
This session examined cancer risk through an environmental and public health lens, highlighting the extent to which cancer burden is shaped by modifiable exposures rather than biology alone. A central theme was the recognition that cancer is not only a clinical or genetic condition, but also a social and environmental disease, with a substantial proportion of cases linked to preventable risk factors. Global evidence suggests that up to 40% of cancers are attributable to modified exposures, including environmental and occupational risks. Dr. Githanga outlined the biological mechanisms through which environmental exposures drive carcinogenesis, including DNA damage, chronic inflammation, epigenetic dysregulation and impaired immune surveillance. These pathways act cumulatively over time, often with long latency periods between exposure and disease manifestation.
Real-world examples such as air pollution, aflatoxin exposure and oncogenic infections illustrate how environmental context directly shapes cancer patterns, particularly in low- and middle-income settings where exposure levels are higher and regulatory systems less robust. Building on this, Dr. Nyangasi emphasized that a significant proportion of cancer burden is preventable, with WHO frameworks highlighting the importance of population-level interventions targeting modifiable risk factors, including environmental regulation, vaccination and lifestyle-related risks.
Dr. Espina introduced the World Code Against Cancer framework, which translates complex scientific evidence into clear, actionable recommendations for individuals, health systems and policymakers. The framework underscores the importance of moving beyond individual behavior change towards coordinated, multi-sectoral prevention strategies. Across the session, a consistent message emerged: meaningful reductions in cancer burden will depend on shifting upstream towards prevention, regulation and system-level action
Key Takeaways

A substantial proportion of cancers are linked to modifiable environmental and behavioral exposures.
Environmental carcinogenesis occurs through multi-pathway biological mechanisms over time.
Exposure to risk is uneven and shaped by social and economic conditions.
Population-level interventions have greater impact than individual behavior change alone.
Effective cancer control requires alignment between clinical practice, public health and policy.

Management of Biliary and Gall Bladder Tumours
2026-02-19 19:00 - 20:30
SUMMARY
Advances in the Multidisciplinary Management of Biliary and Gallbladder Tumours
Speakers: Prof. Elly Ogutu, Dr. Mohan Ramchandani, Dr. Kausik Bhattacharya, Dr. M. Vamshi Krishna
Date: 19 February 2026
This session examined the management of biliary and gallbladder tumours through a multidisciplinary lens, highlighting the importance of coordinated approaches across endoscopy, surgery and oncology in improving patient outcomes.
A central theme was the role of accurate and timely diagnosis, with particular emphasis on tissue acquisition and the contribution of advanced endoscopic techniques in guiding clinical decision-making. The discussion underscored how delays or limitations in diagnostic pathways can significantly influence treatment options and outcomes.
Through the KNH–UoN strategic training partnership and collaboration with the Asian Institute of Gastroenterology, the session reflected the value of regional expertise and diaspora engagement in strengthening clinical capacity and expanding access to specialised skills.
From a clinical perspective, evolving therapeutic strategies—including advances in surgical techniques and radiation oncology—were highlighted as critical components of care, particularly when integrated within a multidisciplinary framework that supports individualized treatment planning.
Across the session, a consistent message emerged: improving outcomes in biliary and gallbladder cancers will depend on strengthening diagnostic pathways and ensuring coordinated, multidisciplinary care across the patient journey.
Key Takeaways

Early and accurate diagnosis remains central to effective management.
Advanced endoscopic techniques play a key role in tissue sampling and staging.
Multidisciplinary coordination improves treatment planning and outcomes.
Regional and diaspora collaboration strengthens clinical capacity.
Integration of surgical, endoscopic and oncological care is essential.

Precision Pathways in Lymphoma
2026-02-26 19:00 - 20:30
Date: 26th February 2026Time: 7:00 PM – 8:30 PM (EAT)

Speakers
ModeratorDr Anne MwirigiConsultant Haematologist & Assistant Professor, AKUH
Dr Rohini RadiaConsultant in BMT and Haematology, Nairobi West HospitalStrategic Alignment in Lymphoma: From Precise Diagnosis to Clinical Excellence
Dr Jonathan WawireConsultant Anatomic Pathologist & Assistant Professor, AKUHLymphoma Diagnostic Algorithm in Routine Practice
Highlights
This session explored how lymphoma care is increasingly shaped by the alignment between diagnostic precision and therapeutic decision-making, particularly in settings where access to advanced diagnostics remains variable.
A central theme was the shift from morphology-led classification alone to a multi-parameter diagnostic approach, integrating clinical context, histopathology, immunophenotyping and where available, molecular profiling. As emphasized during the discussion, classification is no longer purely descriptive: it directly determines treatment pathways, prognosis and eligibility for emerging therapies.
Dr. Wawire outlined a structured diagnostic framework anchored on architecture, cytology and clonality, with morphology guiding the initial pathway and targeted immunohistochemistry refining classification. In routine practice, a focused IHC panel (CD20, CD3, CD5, CD10, Cyclin D1) remains sufficient to classify most lymphomas and support timely clinical decisions.
Importantly, the session addressed the practical realities of diagnostic limitations. The distinction between “Not Otherwise Specified (NOS)” and “Not Further Classified (NFC)” was highlighted as a clinically responsible approach where molecular testing is unavailable maintaining transparency while ensuring patients are still appropriately managed.
Building on this, Dr. Radia emphasized that improved outcomes depend on early alignment between diagnostics, treatment selection and delivery systems. In practice, delays in diagnostic workflows or limited access to molecular testing can directly influence treatment choices and patient outcomes making coordination across pathology, oncology and imaging essential.
As treatment options expand, from immunochemotherapy to targeted agents, CAR-T therapies and bispecific antibodies, the need for early risk stratification and timely decision-making becomes even more critical, particularly in balancing efficacy, cost and access within real-world settings.
Across the case discussions, a consistent message emerged: the quality and timeliness of diagnosis remain central to achieving better outcomes in lymphoma care.
Key takeaways:

Lymphoma classification now relies on integrated clinical, morphological and molecular assessment.
Focused IHC panels remain highly effective in routine and resource-limited settings.
“NFC” supports safe, transparent reporting when advanced testing is unavailable.
Diagnostic delays and access gaps can directly impact treatment decisions.
Early alignment across disciplines is essential to optimize outcomes.

Women in Oncology
2026-03-05 19:00 - 20:30
Women in Oncology this International Women’s Day!
Join us for a powerful CPD Accredited webinar hosted by KESHO — Kenya Society of Haematology & Oncology
Date: 5th March 2026
Time: 7:00 PM – 8:30 PM EAT
Moderator:

Dr. Gladwell Kiarie — Medical Oncologist, The Nairobi Hospital

Speakers:

Prof. Verna Vanderpuye

Senior Consultant Clinical Oncologist & Deputy Director, National Centre of Radiotherapy, Oncology and Nuclear Medicine, Korle-bu Teaching Hospital, Accra, Ghana Topic: Legacy and Leadership: Mentorship from Women Advancing Oncology in Africa

Dr. Chemtai Mungo

Assistant Professor of Obstetrics and Gynaecology & Physician-Scientist, University of North Carolina at Chapel Hill Topic: Purpose-Driven Careers: Global Health, Research and Women’s Impact in Oncology

Dr. Anne Mwirigi

Consultant Haematologist and Assistant Professor, Aga Khan University Hospital Topic: Growing in Specialised Oncology: Lessons in Haematology

Prof. Nazik Hammad

Professor of Medical Oncology, Saint Michael’s Hospital and University of Toronto Topic: Building Impactful Careers in Global Oncology: Mentorship, Leadership and Equity in Cancer Care

Multiple Myeloma Care in Western Kenya
2026-03-12 19:00 - 20:30
Event Title: The Journey of Multiple Myeloma Care in Western Kenya
Accreditation: CPD Accredited

Date: 12th March 2026
Time: 7 PM – 8:30 PM EAT
Organization: KESHO (Kenya Society of Haematology & Oncology)

Moderator:

Dr. Matilda Ongondi: Consultant Physician and Clinical Haemato-Oncologist, Kenyatta National Hospital.

Speakers

Dr. Teresa Lotodo: Senior Lecturer & Consultant Pathologist (AP/CP)Topic: Modern Diagnostic Paradigms in Multiple Myeloma: From Morphology to Molecular Risk Stratification
Dr. Rohini Radia: Consultant in BMT and HaematologyTopic: Contemporary Management of Multiple Myeloma: Sequencing, Cellular Therapies and Risk-Adapted Strategies
Dr. Beatrice Melly: Clinical Haematologist, Moi Teaching and Referral HospitalTopic: Building Sustainable Myeloma Care Pathways: Access, Infrastructure and Multidisciplinary Integration
Hightlights

This session examined how multiple myeloma care is evolving within the Kenyan context, bringing together perspectives on diagnostics, treatment advances and system-level delivery.
A central theme was the contrast between rapid global therapeutic progress and the realities of access and infrastructure in low- and middle-income settings. While survival outcomes have improved significantly with the introduction of proteasome inhibitors, immunomodulatory agents and anti-CD38 therapies, translating these gains into routine practice remains uneven.
The discussion highlighted the importance of accurate and timely diagnosis, with a shift from morphology-based approaches towards molecular and cytogenetic risk stratification to guide treatment decisions.
From a clinical perspective, modern management is increasingly risk-adapted, incorporating quadruplet induction regimens, autologous stem cell transplantation and maintenance strategies. Emerging therapies, including CAR-T cells and bispecific antibodies are redefining outcomes in relapsed disease, though access remains limited in many settings.
At a systems level, the AMPATH multiple myeloma program was presented as a model of how coordinated care can be built through partnerships, integrating clinical care, training and research within a learning health system. The approach emphasizes improving access, strengthening diagnostic and treatment infrastructure, and embedding multidisciplinary care pathways to support patients across the disease course.
Across the session, a consistent message emerged: advancing myeloma care requires not only better therapies, but systems capable of delivering them.
Key Takeaways

Myeloma outcomes are improving with novel and combination therapies.
Accurate diagnosis and risk stratification are central to management.
Standard care includes quadruplet induction, ASCT and maintenance therapy.
CAR-T and bispecific antibodies are reshaping relapsed disease care.
Sustainable progress depends on access, infrastructure and integrated care models.

Renal Cell Carcinoma: Evidence-Based Integration of Surgery and Systemic Therapy
2026-03-19 19:00 - 20:30
Evidence-Based Integration of Surgery and Systemic Therapy
Date: 19th March 2026Time: 7 PM – 8:30 PM EAT
MODERATORDr. Amina K. HabibMedical Oncologist, Aga Khan University Hospital, Nairobi
Dr. Carnjini YogeswaranConsultant Urological Surgeon | Kenyatta National HospitalTopic: Surgical Management of Locally Advanced and Oligometastatic Renal Cell Carcinoma
Dr. Douglas NyandikaPhysician and Medical Oncologist | The Nairobi HospitalTopic: Adjuvant and Metastatic Systemic Therapy in Renal Cell Carcinoma
Highlights
This session examined the evolving management of renal cell carcinoma (RCC), focusing on how surgical and systemic approaches are increasingly integrated across the disease continuum.
A central theme was the importance of risk-adapted, multidisciplinary care, particularly in settings where many patients are still present with advanced diseases. While improved imaging has increased incidental detection globally, late-stage presentation remains common in Kenya, shaping both prognosis and treatment strategy.
From a surgical perspective, nephron-sparing surgery remains standard for localized diseases, while radical nephrectomy and complex resections play a critical role in locally advanced cases. In oligometastatic disease, cytoreductive nephrectomy and metastasis-directed therapy may offer benefit in carefully selected patients, particularly when integrated with systemic treatment strategies.
Systemic therapy has expanded significantly, with immune checkpoint inhibitors and targeted therapies now forming the backbone of treatment in advanced disease. Evidence from key trials demonstrates improved survival outcomes with combination regimens, reinforcing a shift towards early and strategic use of systemic therapy, particularly in metastatic and high-risk settings.
In the adjuvant setting, therapies such as pembrolizumab have shown disease-free and overall survival benefit in selected high-risk patients, highlighting the importance of post-surgical risk stratification and follow-up.
However, translating these advances into routine practice remains constrained by access, cost and infrastructure. The discussion underscored the need for context-specific treatment pathways, supported by multidisciplinary decision-making and strengthened health systems.
Across the session, a consistent message emerged: optimal RCC outcomes depend on deliberate integration—of surgery, systemic therapy and patient-centered decision-making.
Key Takeaways

RCC management requires integration of surgical and systemic therapies.
Late-stage presentation remains a key challenge in many settings.
Nephron-sparing and radical surgery remain central to localized and advanced disease.
Immunotherapy and targeted agents are transforming metastatic RCC outcomes.
Adjuvant therapy is increasingly relevant in high-risk post-surgical patients.
Access, cost and infrastructure continue to shape real-world implementation.

Optimizing Care in Colorectal Cancer
2026-03-26 19:00 - 20:30
Date: 26th March 2026
Time: 7 PM – 8:30 PM EAT
Moderator

Dr. Andrew Odhiambo Medical Oncologist, The Nairobi Hospital; Thematic Head & Program Director, Medical Oncology, UON

Speakers
Dr. Alex Muturi Colorectal Surgeon & Surgical Gastroenterologist, Kenyatta University Teaching, Research and Referral Hospital Locally Advanced Colon Cancer: Timing of Surgery Relative to Systemic Treatment
Dr. Caroline Tonio Medical Oncologist, Clinical Research Fellow (Clinical Trials), The Christie NHS Foundation Trust, UK & KUTRRH, Kenya “Too Young for Colorectal Cancer?” Understanding the rise of EOCRC and its clinical impact.

CLICK TO REGISTER

Treatment in Esophageal Cancer
2026-04-09 19:00 - 20:30
THE ROLE OF MULTIMODAL Treatment in Esophageal Cancer
Date: 9th April 2026 Time: 7 PM – 8:30 PM EAT
MODERATOR
Dr. Omar Abdihamid Clinical Oncologist, Garissa Regional Cancer Center | Vice President (EA), African Organisation for Research and Training in Cancer
SPEAKERS
Dr. Juma Odoro Cardiothoracic and vascular surgeon, JOOTRH Kisumu and Head of Unit Surgical Management of Esophageal Cancer
Dr. Rogers Mongare Consultant Clinical and Radiation Oncologist at Kenyatta National Hospital (KNH) The Role of Radiotherapy in the Management of Esophageal Cancer
Dr. Kevin Makori Consultant Clinical & Radiation Oncologist, Homa Bay County Teaching and Referral Hospital | Clinical Trials Investigator, Victoria Cancer Care & Research Center, Nyamira Management of Metastatic Esophageal Cancer: Advances in Targeted and Combination Therapies

CLICK TO REGISTER

Bridging Surgery and Oncology in Head & Neck Cancer
2026-04-16 19:00 - 20:30
Moderator: Dr. Ahmed Komen
Speakers: Dr. Anthony Kenyanya, Dr. Anthony Ndiritu
Date: 16 April 2026

This session explored the management of head and neck cancer with particular attention to how surgical decisions and oncology pathways must align from the outset. Through oral cavity cancer as a key focus, the session examined resectability, margins, nodal management, reconstruction, adjuvant therapy and functional outcomes.
A central theme was that treatment planning must go beyond tumour removal. Dr. Anthony Kenyanya highlighted the importance of staging, imaging, pathology, dental and nutritional assessment, surgical access, margin planning and neck node evaluation. In oral cavity cancers, surgical success depends not only on clear oncologic resection, but also on the ability to reconstruct defects and preserve speech, swallowing, appearance and quality of life.
The discussion also emphasised the challenge of late presentation and complex anatomy. Selective neck dissection, sentinel node considerations, access procedures such as mandibulotomy, and the reconstructive ladder were framed as tools for balancing disease control with morbidity. The role of the pathologist and margin assessment was highlighted as central to determining risk and guiding further treatment.
Dr. Anthony Ndiritu built on this by outlining how radiotherapy and chemoradiation fit into early, locally advanced, post-operative, recurrent and metastatic diseases. Early-stage disease may often be treated with a single modality, while locally advanced disease requires careful integration of surgery, radiotherapy and chemotherapy.
Positive margins and extranodal extension were discussed as major indications for post-operative chemoradiation, with timely initiation of treatment after surgery being important. The session also addressed treatment technique, patient fitness, nutrition, supportive care and the need to tailor recommendations to the services and expertise available.
Across the session, a consistent message emerged: head and neck cancer care is as much about function, coordination and follow-through as it is about disease control.
Key Takeaways

Head and neck cancer decisions must integrate tumour stage, resectability, patient fitness and functional outcomes.
Margin planning, pathology reporting and neck node assessment directly shape adjuvant treatment decisions.
Surgery requires strong reconstruction and rehabilitation planning to preserve speech, swallowing and appearance.
Locally advanced disease often needs combined-modality treatment through an MDT approach.
Positive margins and extranodal extension are key triggers for post-operative chemoradiation.
Supportive care, nutrition and patient navigation are essential to treatment completion.

Multidisciplinary Management of Testicular Cancer
2026-04-30 19:00 - 20:30
Moderator: Dr. Muigai Mararo
Speakers: Dr. Dedan Opondo, Dr. Joseph Abuodha, Dr. George Ogweno
Date: 30 April 2026

This session marked Testicular Cancer Awareness Month with a multidisciplinary discussion on diagnosis, primary management, advanced disease, relapse and fertility preservation.
A central theme was that testicular cancer is highly curable when investigated and managed promptly, but cure depends on disciplined staging and risk stratification. Dr. Dedan Opondo outlined the importance of early clinical recognition, scrotal ultrasound, serum tumour markers, cross-sectional imaging and radical inguinal orchiectomy. The session reinforced that suspected testicular cancer should not be delayed, particularly because some germ cell tumours can progress rapidly.
Staging was presented as a practical foundation for management. Tumour markers such as AFP, beta-HCG and LDH, together with nodal imaging and histology, help distinguish seminomatous from non-seminomatous disease and guide decisions on surveillance, chemotherapy, radiotherapy and retroperitoneal lymph node dissection. The discussion also highlighted the technical and fertility-related implications of retroperitoneal surgery in young men.
Dr. Joseph Abuodha reviewed advanced and relapsed disease, emphasising that treatment remains strongly anchored in surgery, cisplatin-based chemotherapy, radiotherapy and surveillance rather than newer targeted or immunotherapy approaches. Across stages, the emphasis was on matching intensity to risk—avoiding both overtreatment and undertreatment—while recognising that even metastatic disease can remain curable with the right treatment strategy.
Dr. George Ogweno brought fertility preservation into the core of cancer care. He underscored the need for early oncofertility counselling, sperm banking where possible before treatment, and stronger collaboration between oncology, urology, fertility specialists, laboratories and counsellors. The discussion also reflected Kenya’s service realities, including limited fertility centres and the need for clearer pathways, consent and long-term storage planning.
Across the session, a consistent message emerged: testicular cancer care must protect both survival and survivorship.
Key Takeaways

Early recognition, tumour markers, imaging and radical inguinal orchiectomy are central to initial management.
Risk stratification using histology, TNM stage and post-operative markers guides treatment intensity.
Seminoma and non-seminoma pathways differ and should not be managed interchangeably.
Cisplatin-based chemotherapy remains central in advanced and relapsed disease.
Surveillance is appropriate only when reliable follow-up is possible.
Fertility counselling and sperm preservation should be discussed as early as possible.

From Data to Discovery: Leveraging Registries and Clinical Insights to Advance Research
2026-05-07 19:00 - 20:30
Moderator: Rebecca Mwakichako
Date: 7th May 2026
Speakers: Dr. Thomas Chatzikonstantinou, Ms. Anne Korir
This session examined how routine clinical data can be transformed into meaningful research evidence, with a focus on real-world data, clinical registries and everyday documentation as a foundation for local oncology research.
A central theme was the value of real-world evidence as a complement to randomized controlled trials. Dr. Thomas Chatzikonstantinou outlined how registries and clinical databases can help answer questions on treatment patterns, long-term outcomes, low-prevalence biomarkers, health economics and implementation across diverse settings. He emphasized that good research begins with realistic questions, clear endpoints and attention to data quality.
Ms. Anne Korir grounded the discussion in the Kenyan cancer registry experience, highlighting how paper files, unstructured notes, missing staging information, weak follow-up documentation and inconsistent residence or risk-factor data can limit the research value of clinical records. She underscored the need for standardization, digitization, regular data cleaning and ethical governance.
Across the session, a consistent message emerged: every clinical encounter can contribute to discovery when documentation is structured, complete and designed with future learning in mind.
Key Takeaways

Real-world data complements clinical trials by showing how care is delivered in routine practice.
Routine clinical notes can generate locally relevant oncology research questions.
Standardized documentation is essential for usable research and registry data.
Cancer registries remain critical for surveillance, policy and outcome tracking.
Collaboration between clinicians, registries and research institutions can strengthen local evidence generation.

Melanoma Care in Practice: Integrating Dermatology, Surgery & Oncology
2026-05-14 19:00 - 20:30
Moderator: Dr Stephen Chege
Date: 14th May 2026
SPEAKERS: Dr. Hannah Wanyika, Dr. Esther Gathura, Dr. Angela McLigeyo
This session examined melanoma care across the clinical pathway, from recognition of suspicious skin lesions to biopsy, excision, reconstruction, staging and systemic treatment.
A central theme was the importance of early suspicion and timely tissue diagnosis. Dr. Hannah Wanyika highlighted practical indications for biopsy, including new or changing pigmented lesions, non-healing ulcers, evolving moles and lesions that differ from surrounding skin. The discussion reinforced the use of the ABCDE approach and the “ugly duckling” sign, while emphasizing that changing lesions on the palms, soles, nails and scalp should not be dismissed.
Dr. Esther Gathura explored the surgical and reconstructive dimensions of melanoma care, particularly the realities of acral melanoma, which is common in African populations and often presents late. She emphasized the role of mapping biopsies, Breslow thickness, ulceration, nodal assessment and multidisciplinary planning in balancing oncologic safety with function, especially for weight-bearing areas of the foot.
Dr. Angela McLigeyo outlined the major advances in systemic therapy for advanced melanoma, including immune checkpoint inhibitors, targeted therapy and emerging treatment strategies. While immunotherapy has transformed outcomes globally, the session also acknowledged access, affordability and the urgent need for local data to guide treatment decisions in Kenya and the region.
Across the session, a consistent message emerged: optimal melanoma care depends on early recognition, accurate biopsy, careful staging, function-preserving surgery and realistic access to effective systemic therapy.
Key Takeaways

Changing pigmented lesions, non-healing ulcers and suspicious nail or acral lesions require timely biopsy.
The ABCDE rule and “ugly duckling” sign remain useful tools in clinical assessment.
Acral melanoma presents distinct diagnostic and surgical challenges in African settings.
Surgical management must balance clear margins, staging and functional reconstruction.
Immunotherapy and targeted treatment have changed advanced melanoma care, but access and local evidence remain key challenges.

Bladder Cancer Care
2026-05-21 19:00 - 20:30
SPEAKERS: Dr. Patrick Mbuthia, Dr. Helena Musau, Dr Mohammed Ezzi
Date: 21st May 2026
Moderator: Dr. Sitna Mwanzi
This session examined bladder cancer through a multidisciplinary lens, bringing together surgical, radiotherapeutic and systemic treatment perspectives across the continuum of care.
A central theme was the need for accurate staging and risk-adapted management. Dr. Patrick Mbuthia discussed the role of transurethral resection of bladder tumour (TURBT) in diagnosis, staging and treatment, particularly for non-muscle invasive disease. The importance of complete resection, adequate detrusor muscle in the specimen, careful imaging and attention to complications was emphasized as central to subsequent treatment decisions.
Dr. Helena Musau highlighted the evolving role of radiotherapy in bladder preservation, especially through tri-modality therapy combining maximal TURBT, concurrent chemoradiation and structured response assessment. The discussion also addressed patient selection, surveillance, salvage options, palliative radiotherapy for symptoms, and the value of newer radiotherapy techniques in reducing toxicity while preserving quality of life.
Dr. Mohammed Ezzi reviewed systemic treatment across non-muscle invasive, muscle invasive and metastatic bladder cancer. He outlined the role of intravesical therapy, BCG, cisplatin eligibility, immunotherapy, maintenance strategies and emerging options such as antibody-drug conjugates and targeted agents, while noting that cost and availability continue to shape real-world treatment in Kenya.
Across the session, a consistent message emerged: improving bladder cancer outcomes requires timely diagnosis, high-quality TURBT, multidisciplinary decision-making and treatment pathways that reflect both evidence and local access reality.
Key Takeaways

Bladder cancer management depends on accurate staging and distinction between non-muscle invasive and muscle invasive disease.
High-quality TURBT with adequate muscle sampling is central to diagnosis and treatment planning.
Trimodality therapy offers bladder preservation for carefully selected patients.
Systemic therapy is rapidly evolving with immunotherapy, maintenance approaches and antibody-drug conjugates.
Local data are needed to address African patterns of disease, including schistosomiasis-associated squamous cell carcinoma.

The Brain Tumour Journey
2026-05-28 19:00 - 20:30
Speakers: Dr. Michael Magoha; Dr. Sarah Muma; Dr. Parmenas Minda Okemwa
Moderator: Mr. David L. Oluoch-Olunya
The Brain Tumour Journey brought together neurosurgery, paediatric haemato-oncology and neuropathology perspectives to examine how multidisciplinary collaboration can improve care for patients with brain tumours. The session positioned brain tumour management as a continuum, from first symptoms and referral to surgery, pathology, oncology treatment, rehabilitation, follow-up and family support.
Dr. Michael Magoha opened the session by reframing the brain tumour journey around the patient experience. He noted that brain tumours often carry fear and uncertainty, yet they are not a single diagnosis or a uniform prognosis. With more than 150 tumour types and subtypes, the patient’s pathway can vary widely. His presentation highlighted the role of patient navigation in helping individuals move through imaging, surgery, pathology, endocrine review, oncology care and long-term follow-up without being lost in fragmented systems.
Dr. Sarah Muma focused on the multidisciplinary management of childhood brain tumours in Kenya. She highlighted that brain and CNS tumours appear under-recognised in local and African childhood cancer data, suggesting delays in diagnosis and referral. Children may present with persistent headaches, vomiting, visual changes, seizures, gait or coordination problems, abnormal head growth, behavioral changes or endocrine-related symptoms. The discussion emphasized the need for a higher index of suspicion, especially when symptoms are progressive, recurrent or not responding as expected.
The session also examined Kenyan system-level challenges, including limited access to timely imaging, prolonged pathways between surgery and radiotherapy, scarcity of formal paediatric neuro-oncology programs and treatment abandonment. Dr. Muma described the value of neuro-oncology multidisciplinary clinics, where patients and families can receive coordinated input from neurosurgery, oncology, radiology, pathology, rehabilitation, counselling and navigation teams within a more structured care pathway.
Dr. Parmenas Minda Okemwa closed the presentations by discussing the principles and diagnostic challenges of brain tumour pathology. He emphasized that pathology remains the gold standard for diagnosis, but modern brain tumour care increasingly depends on integrated reporting that combines clinical context, radiology, histology, immunohistochemistry and molecular testing. His presentation underscored the need for adequate tissue sampling, stronger neuropathology capacity, expanded diagnostic panels, molecular testing access and regular multidisciplinary tumour board discussions.
Across the session, the message was clear: improving brain tumour outcomes requires coordinated systems, not isolated excellence. Timely diagnosis, accurate pathology, surgical expertise, oncology planning, patient navigation, rehabilitation and survivorship support must work together if patients are to receive care that is clinically sound, humane and sustainable.
Key Takeaways

Brain tumour care is a journey, not a single event. Patients often require coordinated input across imaging, surgery, pathology, oncology treatment, rehabilitation and follow-up.
Patient navigation can reduce fragmentation. Navigators help patients and families move through complex health systems and reduce the risk of missed appointments, delayed reviews or incomplete follow-up.
Children may present with subtle or progressive symptoms. Persistent headaches, seizures, visual changes, gait problems, behavioural changes or endocrine symptoms should prompt a high index of suspicion.
Multidisciplinary clinics can shorten delays. Same-day or coordinated review by several specialists can improve treatment planning and reduce the burden on families.
Accurate diagnosis depends on integrated pathology. Histology remains central, but immunohistochemistry and molecular testing increasingly guide classification, prognosis and treatment options.
Kenya’s neuro-oncology systems are advancing but need strengthening. Referral pathways, registries, specialist training, diagnostic capacity, molecular testing access and survivorship systems remain key priorities.

Strengthening Haemato-Oncology Care
2026-06-11 19:00 - 20:30
Date: 11th June 2026 Time: 7 PM – 8:30 PM EAT
CPD Accredited
Moderator Prof. John Weru Pain and palliative medicine specialist, palliative care section head. Chief Medical officer and Associate Dean, Clinical Affairs at AUHN.
Dr. Eve Namisango Executive Director, The African Palliative Care Association Palliative Care Research in Africa for Haemato-Oncology
Prof. Sayed Karar Professor, Department of Medicine at Aga Khan University; Acting Chief Medical Information Officer Introduction to Palliative Care

Nutrition into Oncology
2026-06-18 19:00 - 20:30
Integrating Nutrition into Oncology Practice
Fueling Better Outcomes
📅 Date: 18th June 2026
🕖 Time: 7 PM – 8:30 PM EAT
🏅 CPD Accredited
MODERATOR
Kennedy Okinda
Oncology Nutrition Specialist, Mwai Kibaki Referral Hospital
SPEAKER
Njoki Karanja
Oncology Nutrition Specialist
Nutrition in Cancer Care: From Treatment to Recovery
SPEAKER
Dr. Andrew Odhiambo
Medical Oncologist, The Nairobi Hospital; Thematic Head & Program Director, Medical Oncology, UON
The Clinical Impact of Nutrition on Cancer Outcomes
